JOHN JOHNSON - 08 Jun 2022 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role: Director
Signature: /s/ Beth Hecht as Attorney-in-Fact
Issuer symbol: XERS
Transactions as of: 08 Jun 2022
Net transactions value: $0
Form type: 4
Filing time: 09 Jun 2022, 17:13:38 UTC
Previous filing: 03 Jun 2022
Next filing: 24 Jun 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	XERS	Common Stock	Award	$0	+15,000	+3.1%	$0.000000	493,312	08 Jun 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	XERS	Stock Option (Right to Buy)	Award	$0	+25,000		$0.000000	25,000	08 Jun 2022	Common Stock	25,000	$2.10	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 8, 2023 or the date of the Company's next annual meeting of stockholders.
F2	Such options will vest in full upon the earlier to occur of June 8, 2023 or the date of the Company's next annual meeting of stockholders.